Video
October 11, 2024
Hear about the “Strengths-Based Model of Neurodiversity” and how it can help neurodiverse individuals be successful in finding employment and in maximizing their professional potential
Communications
Diversity
Article
October 11, 2024
Virologist Sukrit Silas hopes to turn bacteria-killing viruses into new therapies that hold promise against even the most persistent superbugs.
News Release
Profile
Virology
Gladstone in the News
October 9, 2024
Forbes—The world woke up 17 years ago to an astounding scientific breakthrough: a team of Japanese scientists led by Shinya Yamanaka—now an investigator at Gladstone—had reprogrammed skin cells to resemble an embryonic state. In this interview, Yamanaka shares fascinating insights about the backstory of his work and the doors it is starting to open for patients today.
Gladstone Experts
Yamanaka Lab
Stem Cells/iPSCs
Gladstone in the News
September 26, 2024
ABC7 News—The most commonly reported symptom of long COVID is brain fog, which interferes with your ability to think clearly, remember things, and focus on a task. Senior Investigator Katerina Akassoglou explains the findings from her study that shed new light on what causes brain fog and the many other brain-related symptoms of long COVID and COVID-19.
Gladstone Experts
COVID-19
Akassoglou Lab
Article
September 20, 2024
Longtime Gladstone supporter Darlene Hines reflects on her journey of learning, growth, and giving after her husband’s passing
Donor Stories
Gladstone in the News
September 16, 2024
San Francisco Business Times—The world’s first CRISPR-based drug that alters the genetic code is on the market. Thousands of other therapies using gene editing or stem cell technologies are in the works and offer potential cures. But how will society pay for these life-saving drugs? In this opinion piece, Gladstone President Deepak Srivastava shares his views on a new world of medical possibilities.
Gladstone Experts
Srivastava Lab
Article
September 9, 2024
Mucke, director of the Gladstone Institute of Neurological Disease, discusses what's next for Alzheimer’s research, the role of nonprofit research in developing new therapies, and why he's more hopeful than ever for a future where neurodegenerative diseases are fully treatable—and even preventable.
Alzheimer’s Disease
Neurological Disease
Mucke Lab
Aging
Gladstone in the News
September 6, 2024
University of San Francisco—Students in the Master’s in Biotechnology program at the University of San Francisco visited Gladstone to learn about industry-altering scientific breakthroughs and met with Benoit Bruneany, director of the Gladstone Institute of Cardiovascular Disease, and Stephen Freedman, vice president of corporate liaison and ventures.
Gladstone Experts
Gladstone in the News
September 6, 2024
Genetic Engineering & Biotechnology News—Gladstone Investigator Seth Shipman and his team developed a new technology using retrons to engineer bacteria-fighting viruses known as phages, which could be used to kill antibiotic-resistant bacteria.
Gladstone Experts
Shipman Lab
Article
September 5, 2024
The $350 million Gladstone NOW campaign will raise funds to expand Gladstone’s footprint, hire hundreds of additional scientists, and seize emerging opportunities for high-impact biomedical research that can overcome disease.
Philanthropy
Institutional News
News Release